Using CRISPR-Cas9 screening and ChIP analysis, Chen et al. reported that MYCN promotes EZH2 expression by binding to the EZH2 promoter, inhibiting neuronal differentiation in a PRC2-dependent manner, suggesting that EZH2 inhibitors tazemetostat (EPZ-6438) or GSK126 may be used to treat MNA-NB (Chen et al., 2018). The gene discussed is MYCN; the disease is neuroblastoma.